Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Auric Goldfinger's Short List -- Ignore unavailable to you. Want to Upgrade?

To: RockyBalboa who wrote (4122)	11/11/1999 7:47:00 AM
From: DanZ	Read Replies (2) \| Respond to of 19428

InfoStream, If all you see is red ink, then you didn't look closely at the forward looking statements. In just the first six weeks of the fourth quarter, sales of Zicam are more than three times that of the third quarter. This means that when the fourth quarter earnings are released, all you will see is black ink. If Zicam eliminates people's colds in 1 to 2 days, it won't be a fad. It will steal market share from other cold products on the shelf. If Zicam is proven to prevent the common cold, one has to be blinded by bias to think that it will be a fad. Sales won't stop in just the US. Consumers are telling the company that it works in 1 to 2 days. Don't you think it makes sense that they will start selling Zicam internationally soon? The next two to three quarters have the propensity to be blowouts for Gum Tech, and then nicotine gum will take the spotlight. GUMM is a very dangerous short sale. There are only 7.5 million shares outstanding and over 800,000 are already sold short. The forward fundamentals support a higher stock price IMO, and short covering alone, or boxing by shorts, could move this stock well beyond its fair value in the short term. Regards, Dan